• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Su Wei-Guo

    4/16/26 7:55:20 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMA alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Su Wei-guo

    (Last)(First)(Middle)
    C/O IMAGENEBIO, INC.
    2526 HIGH BLUFF DRIVE

    (Street)
    SAN DIEGO CALIFORNIA 92130

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/16/2026
    3. Issuer Name and Ticker or Trading Symbol
    ImageneBio, Inc. [ IMA ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    No securities are beneficially owned.
    /s/ Wei-guo Su04/16/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $IMA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IMA

    DatePrice TargetRatingAnalyst
    11/25/2025$2.00Underperform
    Wedbush
    10/24/2025$30.00Outperform
    Leerink Partners
    More analyst ratings

    $IMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wedbush resumed coverage on ImageneBio with a new price target

    Wedbush resumed coverage of ImageneBio with a rating of Underperform and set a new price target of $2.00

    11/25/25 8:27:54 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on ImageneBio with a new price target

    Leerink Partners initiated coverage of ImageneBio with a rating of Outperform and set a new price target of $30.00

    10/24/25 9:00:36 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.

    SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)

    5/15/26 4:11:25 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by ImageneBio Inc.

    SCHEDULE 13G/A - ImageneBio, Inc. (0001835579) (Subject)

    5/14/26 4:16:48 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B3 filed by ImageneBio Inc.

    424B3 - ImageneBio, Inc. (0001835579) (Filer)

    5/7/26 8:48:19 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ImageneBio to Participate in 2026 Jefferies Global Healthcare Conference in New York

    SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today announced that chief executive officer Kristin Yarema, Ph.D., will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026 and management will participate in one-on-one meetings. Jefferies Global Healthcare Conference in New YorkDate: Thursday, June 4, 2026Time: 12:50 PM EDTWebcast: Linked here and archived for 90 days on events page on the Imagene IR website About ImageneBio, Inc. Imagene is a clinical-stage biotechnology company dedicated to developing therapeutics for patients with immunological, autoimmune and inflammatory diseases with differentiated

    5/27/26 4:30:00 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Reports First Quarter 2026 Financial Results and Provides IMG-007 Program Update

    SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA) ("Imagene" or the "Company") today reported financial results for the quarter ended March 31, 2026, and provided an update for its lead program, IMG-007, a non-T cell-depleting, ADCC-silenced anti-OX40 receptor antagonist with an extended half-life. Company Highlights In April 2026, the Company completed a private placement for gross proceeds of approximately $30 million led by new investor, Coastlands Capital, with participation from Trails Edge Capital Partners and existing investors Omega Funds and OrbiMed, among others. The financing extends the Company's cash runway into the first quarter of 2028 and enables

    5/7/26 4:05:00 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ImageneBio Announces $30 Million Private Placement

    Private placement led by Coastlands Capital with participation from additional new and existing investors Proceeds will support further development of IMG-007 in alopecia areata and late-stage development activities for the ongoing program in moderate-to-severe atopic dermatitis IMG-007 is the lead receptor-targeting, non-depleting OX40 antagonist in active clinical development  SAN DIEGO, April 13, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA)("Imagene" or the "Company") today announced it has entered into a definitive securities purchase agreement with certain institutional investors in a private placement that is expected to result in gross proceeds of approximately $30 million

    4/13/26 7:00:00 AM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Slattery Joseph P bought $95,840 worth of shares (16,000 units at $5.99) (SEC Form 4)

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    12/29/25 4:46:28 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lally Robert B

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    4/20/26 5:43:39 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Su Wei-Guo

    3 - ImageneBio, Inc. (0001835579) (Issuer)

    4/16/26 7:55:20 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Bonita David P

    4 - ImageneBio, Inc. (0001835579) (Issuer)

    4/16/26 7:31:23 PM ET
    $IMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $IMA
    Leadership Updates

    Live Leadership Updates

    View All

    ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer

    Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (NASDAQ:IMA, "Imagene, " or the "Company")), today announced the appointment of Dr. Ben Porter-Brown, a seasoned autoimmune and inflammatory drug developer with experience in the OX40 receptor-ligand (OX40-OX40L) inhibition field, as its Chief Medical Officer. He will be fo

    2/10/26 7:00:00 AM ET
    $IMA
    $MLTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations